EORM is now BSI EHS Services and Solutions - Read more

Registration Open

Join biotech, pharma and medical device colleagues for this unique exchange of EHS trends, issues, strategies and solutions

Tuesday, October 25, 2016
9:00 AM – 4:00 PM
Cal State University East Bay
Hayward, CA


Join biotechnology, pharmaceutical and medical device industry peers and EHS professionals for an information-rich, strategy-packed day devoted exclusively to the latest EHS trends, issues, strategies and solutions affecting research, development and production facilities today.

Presented by BSI EHS Services and Solutions, the EHS Exchange is a unique, concise, cutting edge and affordable opportunity to hear industry leaders share the best environmental, health and safety practices they are employing to address ever-changing compliance requirements and market conditions.

This first Bay Area event will feature expert presentations on:

  • Laboratory Personal Protective Equipment – Lessons Learned
  • EHS Considerations for Biotech Facilities Start-up
  • Lentiviral and Retroviral Vectors – New Post-Exposure Prophylaxis Guidelines
  • TSCA Reform Update and Impacts to the Biotech Industry
  • Updates on CUPA and Zika

The agenda, as well as speaker information, biographies and complete session descriptions are available below, with additional details coming soon.

You can ensure you have a seat at this event – only $75 for the full day of sessions, lunch included – by completing your online registration here today.

We hope to see you there.

For More Information Contact
Jyoti Kumar, CIH 
Principal Consultant, Manager
BSI EHS Services and Solutions
T: +1 510 995 5413 | jyoti.kumar@bsigroup.com


Agenda

8:00 AM – 9:00 AM
Registration, Continental Breakfast, Network

9:00 AM – 10:00 AM
Laboratory Personal Protective Equipment (PPE) – Lessons Learned
Ken Smith, Executive Director, Environmental Health and Safety, University of California Office of the President

10:00 AM – 11:00 AM
TSCA Reform Update and Potential Impact to the Biotech Industry
Mike Cheng, Consultant, BSI; Martin Bermudez, Principal Consultant, BSI

11:00 AM – 12:00 Noon
EHS Considerations of Biotech Facilities Start-Up
Sandra Jamme, Principal, SLJ Business Services

12:00 Noon – 1:00 PM
Lunch

1:00 PM – 2:00 PM
Lentiviral and Retroviral Vectors – New Post-Exposure Prophylaxis Guidelines
Dr. Gary Fujimoto, Occupational Medicine Consultant

2:00 PM – 3:00 PM
CUPA Update (Details TBA)

3:00 PM – 4:00 PM
Zika Update (Details TBA)


Sessions Descriptions

TSCA Reform Update and Impacts to the Biotech Industry
What impact will recent changes to the Toxic Substances Control Act (TSCA) have on you and your organization? For the biotech and other related industries using dangerous chemicals, the recently passed Frank R. Lautenberg Chemical Safety for the 21st Century Act presents a vast array of new compliance challenges. In this session we will examine the new Act – focusing on those elements having the greatest impact on biotech industries – comparing it to the TSCA regulations and detailing implementation timelines. Impacts to current exemption language, the timing and certification of chemical imports, future manufactured products and more will be explained, providing environmental and safety managers with critical insight to these impending changes.

EH&S Considerations for Biotech Facilities Start-ups
EH&S is an essential component that starts early in the process and can define a tenant improvement project. Sandra will explain how biotech and life science organizations can effectively navigate requirements for facility start-ups by understanding the interdependencies of construction, design, budget, schedules, and EHS to successfully deliver complex and time-sensitive projects.

Lentiviral and Retroviral Vectors – New Post-Exposure Prophylaxis Guidelines
This presentation will focus on the more common vectors used in biological laboratories. Issues involving lentiviral and retroviral vectors will include the problems associated with replication-incompetent vectors that can still alter the host’s genome as well as the enhanced range associated with VSV-G pseudotyping and potential health consequences following exposures. New guidelines will be presented regarding post-exposure prophylaxis with antiretroviral agents. The presentation will include issues with the health implications with RNA interference delivered with these vector systems.

EHS Exchange - biotechnology, pharmaceutical and medical device

biotechnology, pharmaceutical and medical device industry

Presented by

BSI